

Real Time Estimates & Accurate Forecasts
Diabetic Retinopathy Treatment Market is expected to grow with a CAGR of 6.3% during the forecast period of 2018 to 2025.
Diabetic retinopathy, also known as diabetic eye disease, is a common retinal complication that arises in diabetic patients due to the damage caused to the retina. It is a medical condition that can be controlled via treatment, but cannot be cured completely. In less severe cases, diabetic retinopathy can be treated with diabetes management, however, in severe cases laser treatment or surgery is required. Self-care treatment of diabetic retinopathy involves the regulation of blood glucose levels by consuming a well formulated diabetic diet. However, treatment via surgery includes procedures such as vitrectomy, laser coagulation, and laser surgery. In addition, medicated treatment involves the administration of anti-VEGF drugs and other steroidal drugs.
The global diabetic retinopathy treatment market is expected to witness growth in its size due to the surging prevalence of diabetes and rise in the number of geriatric populace around the world. However, the lack of skilled professionals, inadequate healthcare facilities, and presence of low-income groups in the developing economies is expected to create hurdles in the growth of diabetic retinopathy market. In terms of region, North America is expected to account for the maximum market share due to the rising incidences of diabetic retinopathy and huge investments in the healthcare sector. Being a consolidated market with intense competition, the market players are focusing on mergers & acquisitions and technological advancements as their main growth strategies.
The report provides detailed qualitative and quantitative analysis of the diabetic retinopathy treatment market. Market size and forecast in terms of value has been provided for the period – (2017-2025), for the segments namely disease type, treatment type, and treatment providers in each of the major regions.
By Disease Type
• Proliferative Diabetic Retinopathy treatment (PDR)
• Non Proliferative Diabetic Retinopathy treatment (NDPR)
By Treatment Type
• Medicines
o Anti-VEGF therapy
o Intraocular steroid injection
• Laser Surgery
• Vitrectomy
By Treatment Providers
• Hospitals
• Ophthalmic Clinics
• Ambulatory Surgical Centers
By Geography
• North America
o U.S.
o Canada
o Mexico
• Europe
o U.K.
o France
o Germany
o Italy
o Spain
o Rest of Europe
• Asia-Pacific
o China
o Japan
o India
o Korea
o Rest of APAC
• South America
o Brazil
o Rest of South America
• Rest of the World
o Middle East
o Africa
CHAPTER 1. INTRODUCTION
1.1. RESEARCH METHODOLOGY
1.1.1. ERC desk research
1.1.2. ERC data synthesis
1.1.3. Data validation and market feedback
1.1.4. ERC data sources
CHAPTER 2. DIABETIC RETINOPATHY TREATMENT MARKET OVERVIEW
2.1. DIABETIC RETINOPATHY TREATMENT MARKET INTRODUCTION
2.2. GLOBAL DIABETIC RETINOPATHY TREATMENT MARKET REVENUE AND GROWTH RATE, 2017-2025
2.2.1. Global Diabetic Retinopathy Treatment Market Revenue (Million USD) and Growth Rate (%), (2017-2025)
CHAPTER 3. GLOBAL DIABETIC RETINOPATHY TREATMENT MARKET BY DISEASE TYPE, 2017-2025
3.1. PROLIFERATIVE DIABETIC RETINOPATHY TREATMENT (PDR)
3.2. NON PROLIFERATIVE DIABETIC RETINOPATHY TREATMENT (NDPR)
3.3. GLOBAL DIABETIC RETINOPATHY TREATMENT MARKET REVENUE BY DISEASE TYPE, 2017-2025
3.3.1. Global Diabetic Retinopathy Treatment Market Revenue (Million USD) and Share (%) By Disease type, 2017-2025
3.3.2. Proliferative Diabetic Retinopathy treatment (PDR) Market Revenue and Growth Rate, 2017-2025
3.3.3. Non Proliferative Diabetic Retinopathy treatment (NDPR) Market Revenue and Growth Rate, 2017-2025
Note: Similar information coverage has been provided for treatment type segment.
CHAPTER 4. GLOBAL DIABETIC RETINOPATHY TREATMENT MARKET BY TREATMENT PROVIDERS, 2017-2025
4.1. HOSPITALS
4.2. OPHTHALMIC CLINICS
4.3. AMBULATORY SURGICAL CENTERS
4.4. GLOBAL DIABETIC RETINOPATHY TREATMENT MARKET REVENUE BY TREATMENT PROVIDERS, 2017-2025
4.4.1. Global Diabetic Retinopathy Treatment Market Revenue (Million USD) and Share (%) By Treatment Providers, 2017-2025
4.4.2. Hospitals Market Revenue and Growth Rate, 2017-2025
4.4.3. Ophthalmic Clinics Market Revenue and Growth Rate, 2017-2025
4.4.4. Ambulatory Surgical Centers Market Revenue and Growth Rate, 2017-2025
CHAPTER 5. GLOBAL DIABETIC RETINOPATHY TREATMENT MARKET BY REGION, 2017-2025
5.1. NORTH AMERICA
5.1.1. U.S.
5.1.2. Canada
5.1.3. Mexico
5.2. EUROPE
5.2.1. U.K.
5.2.2. France
5.2.3. Germany
5.2.4. Italy
5.2.5. Spain
5.2.6. Rest of Europe
5.3. ASIA PACIFIC
5.3.1. China
5.3.2. Japan
5.3.3. India
5.3.4. Korea
5.3.5. Rest of APAC
5.4. SOUTH AMERICA
5.4.1. Brazil
5.4.2. Rest of South America
5.5. REST OF THE WORLD
5.5.1. Middle East
5.5.2. Africa
5.6. GLOBAL DIABETIC RETINOPATHY TREATMENT MARKET REVENUE BY REGION, 2017-2025
5.6.1. Global Diabetic Retinopathy Treatment Market Revenue (Million USD) and Share (%) By Region, 2017-2025
5.6.2. North America Market Revenue and Growth Rate, 2017-2025
5.6.3. Europe Market Revenue and Growth Rate, 2017-2025
5.6.4. Asia Pacific Market Revenue and Growth Rate, 2017-2025
5.6.5. South America Market Revenue and Growth Rate, 2017-2025
5.6.6. Rest of the World Market Revenue and Growth Rate, 2017-2025
CHAPTER 6. MARKET DETERMINANTS
6.1. MARKET DRIVERS
6.2. MARKET RESTRAINTS
6.3. MARKET OPPORTUNITIES
6.4. MARKET DETERMINANTS RADAR CHART
CHAPTER 7. GLOBAL DIABETIC RETINOPATHY TREATMENT MARKET COMPETITION BY SERVICE PROVIDERS
7.1. GLOBAL DIABETIC RETINOPATHY TREATMENT REVENUE AND SHARE BY SERVICE PROVIDERS (2017-2025)
7.1.1. Global Diabetic Retinopathy Treatment Revenue (Million USD) and Share (%) by Service Providers (2017-2025)
7.2. DIABETIC RETINOPATHY TREATMENT MARKET COMPETITIVE SITUATION AND TRENDS
7.2.1. Diabetic Retinopathy Treatment Market Share (%) of Top 3 Service Providers
7.2.2. Diabetic Retinopathy Treatment Market Share (%) of Top 5 Service Providers
CHAPTER 8. COMPANY PROFILES
8.1. AMPIO PHARMACEUTICALS, INC.
8.1.1. Business Overview
8.1.2. Company Basic Information
8.1.3. Diabetic Retinopathy Treatment Product Details
8.1.4. Ampio Pharmaceuticals, Inc. Diabetic Retinopathy Treatment Revenue and Gross Margin
8.2. AERPIO PHARMACEUTICALS
8.2.1. Business Overview
8.2.2. Company Basic Information
8.2.3. Diabetic Retinopathy Treatment Product Details
8.2.4. Aerpio Pharmaceuticals Diabetic Retinopathy Treatment Revenue and Gross Margin
8.3. SIRNAOMICS, INC.
8.3.1. Business Overview
8.3.2. Company Basic Information
8.3.3. Diabetic Retinopathy Treatment Product Details
8.3.4. Sirnaomics, Inc. Diabetic Retinopathy Treatment Revenue and Gross Margin
8.4. BAYER AG
8.4.1. Business Overview
8.4.2. Company Basic Information
8.4.3. Diabetic Retinopathy Treatment Product Details
8.4.4. Bayer AG Diabetic Retinopathy Treatment Revenue and Gross Margin
8.5. ALIMERA SCIENCES, INC.
8.5.1. Business Overview
8.5.2. Company Basic Information
8.5.3. Diabetic Retinopathy Treatment Product Details
8.5.4. Alimera Sciences, Inc. Diabetic Retinopathy Treatment Revenue and Gross Margin
8.6. GENENTECH, INC.
8.6.1. Business Overview
8.6.2. Company Basic Information
8.6.3. Diabetic Retinopathy Treatment Product Details
8.6.4. Genentech, Inc. Diabetic Retinopathy Treatment Revenue and Gross Margin
8.7. THROMBOGENICS
8.7.1. Business Overview
8.7.2. Company Basic Information
8.7.3. Diabetic Retinopathy Treatment Product Details
8.7.4. ThromboGenics Diabetic Retinopathy Treatment Revenue and Gross Margin
8.8. NOVARTIS AG
8.8.1. Business Overview
8.8.2. Company Basic Information
8.8.3. Diabetic Retinopathy Treatment Product Details
8.8.4. Novartis AG Diabetic Retinopathy Treatment Revenue and Gross Margin
8.9. KOWA COMPANY LTD.
8.9.1. Business Overview
8.9.2. Company Basic Information
8.9.3. Diabetic Retinopathy Treatment Product Details
8.9.4. Kowa Company Ltd. Diabetic Retinopathy Treatment Revenue and Gross Margin
8.10. ALLERGAN PLC (ACTAVIS PLC)
8.10.1. Business Overview
8.10.2. Company Basic Information
8.10.3. Diabetic Retinopathy Treatment Product Details
8.10.4. Allergan PLC (Actavis PLC) Diabetic Retinopathy Treatment Revenue and Gross Margin
CHAPTER 9. DIABETIC RETINOPATHY TREATMENT MARKET VALUE CHAIN ANALYSIS
9.1. DIABETIC RETINOPATHY TREATMENT INDUSTRIAL CHAIN ANALYSIS
9.2. CONSUMER ANALYSIS
9.2.1. Consumer 1
9.2.2. Consumer 2
9.2.3. Consumer 3
9.2.4. Consumer 4
• Ampio Pharmaceuticals, Inc.
• Aerpio Pharmaceuticals
• Sirnaomics, Inc.
• Bayer AG
• Alimera Sciences, Inc.
• Genentech, Inc.
• ThromboGenics
• Novartis AG
• Kowa Company Ltd.
• Allergan PLC (Actavis PLC)
• BCN Peptides S.A.
• Regeneron Pharmaceuticals, Inc.
• What was the market size of the Diabetic Retinopathy Treatment Market in 2017 and the expected market size by 2025, along with the growth rate?
• An in-depth analysis of the current impacting factors, opportunities and challenges/restraints in the market
• Which are the largest revenue generating products, services or regions, and their comparative growth rate?
• Which technology is on trend and how would it evolve during the forecast period (2017 – 2025)?
• Which are the leading companies in the Diabetic Retinopathy Treatment Market and their competitive positioning basis their market share, product portfolio, strategic attempts and business focus?